Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Stem Cell & Coagulation Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PROCR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PROCR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PROCR Products |
| Gene Delivery | PROCR Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional cell-based assays. |
View PROCR Products |
| Benchmark Ab | Anti-PROCR Biosimilar Antibody Recombinant positive control for assay validation. Sequence verified. |
View PROCR Products |
| Validator | PROCR siRNA Set For target knockdown verification and specificity controls. |
View PROCR Products |
| Related Target A | PROC (Protein C) Primary physiological ligand for PROCR; essential for competitive binding and coagulation assays. |
View PROC Products |
| Related Target B | F2R (PAR1) Co-receptor involved in the cytoprotective and anti-inflammatory signaling cascade activated by the PROCR-APC complex. |
View F2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity (SEC-HPLC verified). |
| Conformational integrity for cell-based screening | Lentivirus Premade Particles for stable cell line generation, preserving native multi-pass or complex membrane topology. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live PROCR/CD201 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PROCR therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and bispecific constructs targeting cancer stem cells (CSCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the delicate balance between anti-tumor efficacy and the preservation of normal vascular endothelial function.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biotech & Pharma | Solid Tumors (TNBC, Ovarian, Glioblastoma) | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| mAbs (Blocking) | Academic Institutes / Oncology Biotechs | Metastatic Tumors, Hematological Malignancies | Ligand Blocking Assay (Need high-affinity PROC and PROCR recombinant proteins) |
| Bispecific Antibodies | Immuno-oncology Innovators | Advanced Solid Tumors | Cell-based binding and activation assays (Need Lentivirus for stable cell line construction) |